title: Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.
abstract: BACKGROUND
  Dysregulation of the cell cycle is a hallmark of many cancers including ovarian cancer, a leading cause of gynaecologic cancer mortality worldwide.
  
  
  METHODS
  We examined single nucleotide polymorphisms (SNPs) (n=288) from 39 cell cycle regulation genes, including cyclins, cyclin-dependent kinases (CDKs) and CDK inhibitors, in a two-stage study. White, non-Hispanic cases (n=829) and ovarian cancer-free controls (n=941) were genotyped using an Illumina assay.
  
  
  RESULTS
  Eleven variants in nine genes (ABL1, CCNB2, CDKN1A, CCND3, E2F2, CDK2, E2F3, CDC2, and CDK7) were associated with risk of ovarian cancer in at least one genetic model. Seven SNPs were then assessed in four additional studies with 1689 cases and 3398 controls. Association between risk of ovarian cancer and ABL1 rs2855192 found in the original population [odds ratio, OR(BB vs AA) 2.81 (1.29-6.09), P=0.01] was also observed in a replication population, and the association remained suggestive in the combined analysis [OR(BB vs AA) 1.59 (1.08-2.34), P=0.02]. No other SNP associations remained suggestive in the replication populations.
  
  
  CONCLUSIONS
  ABL1 has been implicated in multiple processes including cell division, cell adhesion and cellular stress response. These results suggest that characterization of the function of genetic variation in this gene in other ovarian cancer populations is warranted.
authors.affiliation: Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. cunningham.julie@mayo.edu
authors.forename: J M
authors.initials: JM
authors.lastname: Cunningham
authors.forename: R A
authors.initials: RA
authors.lastname: Vierkant
authors.forename: T A
authors.initials: TA
authors.lastname: Sellers
authors.forename: C
authors.initials: C
authors.lastname: Phelan
authors.forename: D N
authors.initials: DN
authors.lastname: Rider
authors.forename: M
authors.initials: M
authors.lastname: Liebow
authors.forename: J
authors.initials: J
authors.lastname: Schildkraut
authors.forename: A
authors.initials: A
authors.lastname: Berchuck
authors.forename: F J
authors.initials: FJ
authors.lastname: Couch
authors.forename: X
authors.initials: X
authors.lastname: Wang
authors.forename: B L
authors.initials: BL
authors.lastname: Fridley
authors.forename: A
authors.initials: A
authors.lastname: Gentry-Maharaj
authors.forename: U
authors.initials: U
authors.lastname: Menon
authors.forename: E
authors.initials: E
authors.lastname: Hogdall
authors.forename: S
authors.initials: S
authors.lastname: Kjaer
authors.forename: A
authors.initials: A
authors.lastname: Whittemore
authors.forename: R
authors.initials: R
authors.lastname: DiCioccio
authors.forename: H
authors.initials: H
authors.lastname: Song
authors.forename: S A
authors.initials: SA
authors.lastname: Gayther
authors.forename: S J
authors.initials: SJ
authors.lastname: Ramus
authors.forename: P D P
authors.initials: PD
authors.lastname: Pharaoh
authors.forename: E L
authors.initials: EL
authors.lastname: Goode
mesh_terms: D002453:Cell Cycle / Q000235:genetics*; D018844:Cyclin-Dependent Kinases / Q000235:genetics; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D010051:Ovarian Neoplasms / Q000209:etiology / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide
chemical_list: D018844:Cyclin-Dependent Kinases